Peptide Therapeutics Market is Forecasted to Reach US$46.6 bn by 2024

The global market for peptide therapeutics has been dominated by Teva, Novo Nordisk, Eli Lilly, and Sanofi, states Transparency Market Research (TMR) in a research report. These players collectively held a share of over 75% in the global peptide therapeutics market in 2015. These market players are directing thorough research and have taken up different improvement activities to highlight their particular shares in the overall industry, which is probably going to build the competition inside this market, states the research report.
According to a TMR analyst, “The global market for peptide therapeutics was pegged at US$21.3 bn in 2015 and is expected to rise to a valuation of US$46.6 bn by 2024. The market is expected to expand at a 9.10% CAGR from 2016 to 2024.”

Read Report Overview: https://www.transparencymarketresearch.com/peptide-therapeutics-market.html

Immunopeptides to be in High Demand
The report breaks down the worldwide market for peptide therapeutics on the premise of various market parameters. One among them is the kind of molecule, in view of which, the market has been arranged into somatostatin, natriuretic, vasopressin, calcitonin, and immunopeptide. On account of the expanding use of immunopeptide for the treatment of a few conditions, for instance, tumors and cancers, the immunopeptide segment has been enlisting a higher development than others.
Since the treatment of these maladies is complex, more ventures is being made by the key market players in innovative development of various different treatments, among which the immuno treatment is the most supported one. This, thus is foreseen towards positive development of the immunopeptide segment soon, takes note of the investigation.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418

Region-wise, the report sections the overall market for peptide therapeutics into the Middle East and Africa, Europe, North America, Latin America, and Asia Pacific. In 2015, North America procured the main position in the worldwide market with a share of over 38.8%. It is anticipated that this region will hold its position over the time of the conjecture, because of the infrastructural headways in the healthcare and medical industry. The rise of peptide therapeutics as an exceptionally intense medications for the treatment of malignancy and different ailments and the prevalence of market leaders in the U.S. are additionally anticipated to help the North America market for peptide therapeutics in the coming years.
Rising Use of Peptide for Treatment of Cancer to Bolster Adoption
The core reason behind the substantial growth of the global market for peptide therapeutics is the growing prevalence of cancer. As indicated by the WHO, almost 7 million individuals face death from cancer consistently and there will be more than 16 million new growth cases each year by 2020. Since chemotherapy is confronting significant difficulties because of its powerlessness to convey the right measure of medication directly, the utilization of peptides in tumor treatment has expanded, opening new roads for future development.

Buy Peptide Therapeutics Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=418&ltype=S

Going ahead, the rising rate of metabolic issue is probably going to make lucrative prospects for the players operating in the global peptide therapeutics market in the years to come. In any case, the absence of administrative models may confine the market from developing throughout the forecast period.

Umbilical Cord Blood Banking Market is expected to reach US$8,178.1 mn with a CAGR of 11.4% up to 2025

The vendor landscape of the global umbilical cord blood banking market is highly fragmented owing to the presence of several small scale vendors, with the top three vendors collectively accounting for a meagre 7% of the market in 2016, observes Transparency Market Research in a recent report. The rising number of private cord blood banking companies in the global market is expected to make the market further competitive. Although the market is fragmented, it is highly regulated, on domestic as well as international fronts.
Some of the leading players in the market are CBR Systems, Inc., ViaCord Inc., China Cord Blood Corporation, Cord Blood America, Inc., Cryo-Cell International, Inc., Cryo-Save AG, Cordlife Group Ltd., Vita 34 AG, LifeCell, and StemCyte Inc.

Read Report Overview: https://www.transparencymarketresearch.com/umbilical-cord-blood-banking-market.html

Transparency Market Research estimates that the global umbilical cord blood banking market, which valued at US$3,124.4 mn in 2016, will exhibit a strong CAGR of 11.4% from 2017 to 2025, reaching an estimated value of US$8,178.1 mn in 2025.
Private Blood Banks to Remain Most Preferred Storage Option
In terms of type of storage, the global umbilical cord blood banking market earned a large share in its overall revenue from the private cord banks segment. The segment accounted for a massive
65.0% of the global market in 2016 and is expected to remain the dominant segment despite high initial as well as yearly costs incurred for the processing, testing, and storage of cord blood units in private banks. The high level of assurance and security to cord blood provided by private banks, the provision of complete ownership rights to the donor, and flexible collection sites are some of the key factors compelling end-users to prefer private cord banks instead of public cord banks.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19922

North America presently dominates the global umbilical cord blood banking market, accounting for over 38% of the global umbilical cord blood banking market in 2016. The North America market is expected to exhibit strong growth in the next few years due to the increasing demand for stem cell research and public awareness about cord blood banking. Demand for cord blood banking in North America is high in the U.S., which held 83.8% market share in 2016, followed by Canada.
Rising Rate of Hematopoietic Stem Cell Transplantation Drives Market
The key factors encouraging expectant parents to preserve cord blood include the vast rise in the rate of hematopoietic stem cell transplantation, the vast advancements in cord blood processing and storage technologies, increased awareness about stem cell therapy, and increase in applications of cord blood cells in treatment of various diseases. The market expanded at a rapid pace in the past decade also due to the active role of public and private bodied in educating the parental population about the process and benefits of cord blood banking.

Buy Umbilical Cord Blood Banking Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=19922&ltype=S

Umbilical cord blood is a rich source of primitive hematopoietic stem cells. Therefore, it has a strong regenerative potential for stem cell-based therapy for the treatment of non-hematological and hematological diseases. Umbilical cord blood is also used as an alternative to bone marrow treatment. Hematopoietic stem cell transplantation is the treatment of stem cells, usually derived from peripheral blood, bone marrow, or umbilical cord blood. The transplantation is mostly performed for the treatment of bone marrow or blood cancers. Increasing incidences of cancer along with adoption of stem cell treatment in developed countries such as the U.S., the U.K., and Germany have boosted the demand for umbilical cord blood banking, which, in turn, is expected to propel the market.

Homeopathy Product Market to Reach an Opportunity of US$17,486.2 mn by the End of 2024

Transparency Market Research estimates that the global homeopathy product market will exhibit a promising 18.2% CAGR over the period between 2016 and 2024. If the number holds true, the market, which valued at US$3,867.7 mn in 2015, is expected to reach US$17,486.2 mn by 2024.
Middle East and Africa to Provide Promising Growth Opportunities
TMR estimates that the global homeopathy product market, which valued at US$3,867.7 mn in 2015, is expected to reach US$17,486.2 mn by the end of 2024, exhibiting a CAGR of 18.2% over the period between 2016 and 2024. Of the key product varieties in the market, the segment of dilutions is expected to achieve the most promising share in the market’s valuation by the end of forecast period, retaining its dominant position with over 35% of the market by 2024. The segment will also register a strong 17.8% CAGR over the period between 2016 and 2024.

View Report Overview: http://www.transparencymarketresearch.com/homeopathy-product-market.html

In terms of geography, Europe will continue to account for the most significant share in the market throughout the forecast period but will lose prominence to the Middle East and Africa region in terms of growth rate. Over the period between 2016 and 2024, the Europe market for homeopathy products will exhibit an 18.2% CAGR while the MEA market will expand at a 21.1% CAGR.
Aversion to Allopathic Medicine Expected to Increase Homeopathic Medicine Sales
One of the leading factors augmenting the growth of the global homeopathy products market is the growing concern regarding the high usage of allopathic medicine. “People are becoming increasingly aware of the cumulative side-effects that they may contract after prolonged use of allopathic medicine. This is leading consumers towards alternative treatments, including homeopathy. An independent survey had revealed that US$3 bn was spent on homeopathic medicine within North America alone, in 2007. The market has skyrocketed since then and is on the brink of becoming a mainstay in all key regions,” states a TMR analyst.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16460

Quality Standardization Still Lacking in Homeopathic Medicine Manufacture
There is a considerable lack of quality control within the global homeopathy products market and suppliers are suffering because of it. A massive chunk of the market revenue is gathered by small and medium sized business that are scattered over the key regions, making it very difficult to hold a consolidated effort for quality assurance standards implementation. Every manufacturing industry needs to adhere to good manufacturing practices and so far, the global homeopathy products market is not playing its part to the fullest extent. This is compromising the quality of medicines and products to a great extent, creating negative consumer experiences and reducing demand.
The global market for homeopathy products features the presence of a large number of small and medium enterprises, with the top five companies cumulatively accounting for merely over 27% of the overall market in 2015, observes Transparency Market Research (TMR) in a recent report. Despite this, the company Boiron Group held over 17.3% of the market in the said year, a share large enough to have a key influence on the market’s direction. Strong presence across regions such as Europe, North America, Asia Pacific, and Middle East and Africa (MEA) has allowed the company to command a prominent position in the global homeopathy products market so far.

Buy Homeopathy Product Market Research Report @
http://www.transparencymarketresearch.com/checkout.php?rep_id=16460&ltype=S

However, other notable vendors such as Biologische Heilmittel Heel GmbH, A Nelson & Co Ltd, GMP Laboratories of America, Inc., Standard Homeopathic Company (Hyland's, Inc.), Washington Homeopathic Products, Inc., and Homeocan inc., struggle to strengthen their hold on the market amid harsh competition. Strategies such as increased focus on robust marketing and promotion activities, proper usage of the highly influential e-commerce marketplace, and expansion across promising regional markets such as Asia Pacific and Middle East and Africa (MEA) could help companies gain more traction in the global market. 

Electrosurgical Devices Market to Become Worth US$7,963.2 mn by 2024

The global electrosurgical devices market is considered to be a highly fragmented landscape and has a less intensive competition thanks to the existence of a large pool of domestic as well as global players across vital regional markets. Even though the barriers for entry are relatively low for the new entrants, factors such as high degree of fragmentation, excessive competition in terms of prices, increasing research and development expenses can slow down the growth prospects for the new entrants in the global market for electrosurgical devices.
To leverage the overall development opportunities and bolster their hold on the international market, the established players in the market are now concentrating on developing new accessories and products with multimodality application, cutting properties, and improved coagulation. In a recent development of 2016, the launch of APCapplicator electrosurgical hand-piece was developed by ERBE Elektromedizin GmbH. This devices works as both coagulation and vessel cutting purpose and has applications in laparoscopy and open surgery. Development of new and innovative multimodality systems such as robotic surgical systems, to enhance the precision and ease of the surgical procedures is also an upcoming and trending strategy in the global market.

Read Report Overview: https://www.transparencymarketresearch.com/electrosurgical-devices-market.html

The global market for electrosurgical devices was valued at US$4.480 bn in the year 2015. This valuation was estimated to reach to an overall figure worth US$7.963 bn by the edn of 2024. This growth of the global electrosurgical devices market is expected to be achieved with the help of an impressive CAGR of 6.7% over the course of the given forecast period of 2016 to 2024.
With respect to the type of product, the global market for electrosurgical instruments is expected to be dominated by electrosurgical accessories. In terms of geography, the North America market has been leading in the last few years and is expected to continue its dominance over the course of the given forecast period of 2016 to 2024.
Government Backings in Emerging Economies to Drive Market Growth
Across the prominent end use areas such as surgical ambulatory units, specialized clinics, and hospitals, the overall uptake of the electrosurgical devices has grown at a considerable rate thanks to the motivating reimbursement policies and secure coverage of medical bills by the insurance policies in several developed as well as developing economies. The provision of medical insurance enables those are covered to uptake the best surgical choices that are available without having to think cost of surgery as a restraint. This is expected to act as one of the key factors for fuelling an overall development of the global market for electrosurgical devices during the coming years of the aforementioned forecast period.

Request Sample of Report:https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=449

The global market for electrosurgical devices is also driven by the growing focus on the enhancements of the healthcare systems across numerous emerging economies. The government and regulatory bodies are raising more funds for investing in the activities of research and development for advanced medical treatments and surgical devices that are target specific. This is also expected to fuel the all-round development of the global market electrosurgical devices.
Numerous Complexities Related to Electro-surgery to Impede Growth of Market
However, there are some factors that are expected to hamper the growth of the market in the coming years. One of the key factors for impeding the growth of the global market for electrosurgical devices is the possibility of several complications such as post-operative complications and electro-thermal injuries. Other complications such as capacitive coupling, direct coupling, improper applications of these electrosurgical devices, and failure of insulation among others are also expected to add to the apprehension of widespread adoption of electrosurgical devices.

Buy Electrosurgical Devices Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=449&ltype=S

Platelet Rich Plasma Market Opportunity will Rise to US$451.9 mn by 2024

As per the research study, the global market for PRP, which was valued at US$160.0 mn in 2015, is likely to expand at a CAGR of 12.50% during the period from 2016 to 2024 and report an opportunity worth US$451.9 mn by the end of the forecast period. The P-PRP segment, which occupied more than 60% of the overall market in 2015, is expected to remain leading throughout the forecast period.

View Report Overview: http://www.transparencymarketresearch.com/platelet-rich-plasma-market.html

Wide Presence of Leading Players to Ensure North America’s Dominance
The research report has also evaluated the global market for PRP on the basis of its geographical spread. It has identified North America, Asia Pacific, Europe, the Middle East and Africa, and Latin America as the key regional markets for PRP across the world. Supported by the increasing count of orthopedic and cosmetic surgeries, North America led the global market with a majority share in 2015. Further, the wide presence of leading market players and the high awareness level among consumers about PRP therapy and devices are likely to ensure the leadership of this regional market throughout the forecast period.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4021

Asia Pacific is also expected to witness a healthy rise in the adoption of PRP therapies in the near future. The swiftly growing medical tourism industry, presence of well-established local players, increased base of the geriatric population, and the rising awareness regarding PRP among people are projected to boost the Asia Pacific PRP market over the forthcoming years, states the research report.
Increasing Count of Orthopedic Patients to Fuel Demand
“The significant increase in the count of orthopedic patients, worldwide, is the prime factor behind the tremendous progress of the global PRP market,” says a TMR analyst. As PRP therapy curtails the healing time of orthopedic or sports injuries from 4-6 months to 3-5 weeks with surgery, its demand for the treatment of orthopedic surgeries has increased remarkably and this is likely to remain so over the next few years.
The rise in cosmetic surgical procedures is another important factor that is likely to shape the future of the global PRP market. The high cost of PRP products and therapy is expected to hamper the growth of this market to some extent during the forecast period, notes the research study.

Buy Platelet Rich Plasma Market Research Report:
http://www.transparencymarketresearch.com/checkout.php?rep_id=4021&ltype=S

With a larger pool of players operating domestically and a smaller bunch of international participants, the global platelet-rich plasma (PRP) market demonstrates a semi-consolidated landscape. The top five players, namely, Harvest Technologies, Arthrex Inc., Zimmer Biomet, DePuy Synthes, and Stryker Corp. accounted for more than 80% of this market in 2015. Most of these are headquartered in North America. However, their focus is likely to shift towards emerging economies across Asia Pacific in the coming years, as this region is expected to offer lucrative opportunities on account of untapped potential.

Hospital Acquired Infection Treatment Market to Surge at a CAGR of 2.7% by 2024

The global hospital acquired infection treatment market in 2015 was dominated by a handful of players, including Abbott, Pfizer, Inc., Merck & Co., Inc., and Bayer AG. The market is currently in a state of battle with the growing count of generics available in the world, owing to an incoming wave of patent expirations. This could create a problem for players trying to maintain favorable profit margins.
According to a research report released by Transparency Market Research, the highly fragmented global hospital acquired infection treatment market holds a medium level of competition for players of all sizes. Key players are locked in rivalry for the development of treatments for alternative molecule therapies and multi-drug resistant pathogens. At the same time, the threat of new entrants to the existing market is very high, owing to the growing demand for enhanced therapeutics, despite the high entry barriers set by strict regulatory frameworks and capital intensive research and development. The global hospital acquired infection treatment market was valued at US$28.99 bn at the end of 2015 and is expected to expand at a CAGR of 2.7% within a forecast period from 2016 to 2024. By the end of 2024, this market is expected to reach an estimated US$36.61 bn.

Read Report Overview: https://www.transparencymarketresearch.com/hospital-acquired-infection-treatment-market.html

Growing Geriatric Population Propels Nosocomial Treatment Demand in Developed Economies
“There is a multi-tracked set of drivers that are currently augmenting the global hospital acquired infection treatment market. Each driver is directly or indirectly linked to the other. Of the many factors in favor of the market’s growth, the leading factor has to be the growing geriatric population. The elderly – due to their lower physical immunity – are incredibly prone to infections and especially nosocomial ones. Therefore, the growing population of the geriatric is a serious factor that needs to be accounted for within the global hospital acquired infection treatment market,” states a TMR analyst.
Other factors driving the global hospital acquired infection treatment market include the overall condition of healthcare organizations in emerging economies. Their generally lower levels of hygiene, infrastructure maintenance and sterilization techniques are creating a very high demand for nosocomial infection treatments. Countries from Asia Pacific, for instance, are currently showing to be leading in terms of growth rate of demand, thereby attracting several prominent players in the global hospital acquired infection treatment market.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17267

Multi-drug Resistant Bacteria Complicating Market Scenario in Nosocomial Infections Treatments
A key restraint acting on the global hospital acquired infection treatment market currently, is the steady increase in the rate of failures in treatment caused by the growing number of multi-drug resistant bacteria. Given a frequent rate of survival of bacteria after being exposed to drugs that are designed to eliminate them, they are known to develop resistance to them, pressuring the healthcare industry to seek alternative treatments or other forms of drug treatments. There is a growing rate of multi-drug resistant bacteria affecting patients and these infections can prove to be heavily detrimental to a patient’s recovery cycle or even be fatal for them.
“Key players in the global hospital acquired infection treatment market are more likely to have multiple drugs in the pipeline, the approval of which can be a shot in the arm for the market. The focus on HAIs is increasing at a fast rate in emerging economies as well, giving rise to a massive untapped market for patients from the lower and middle income classes. These avenues can prove to be fruitful for players currently established in the global hospital acquired infection treatment market, as well as new entrants in emerging economies,” adds the analyst.

Buy Hospital Acquired Infection Treatment Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=17267&ltype=S

Geriatric Medicines Market is Expanding at a CAGR of 7.3 % by 2023

A recent market report by Transparency Market Research has pegged the global geriatric medicine market to reach US$948 bn by 2023. According to the report the market was valued at US$504.7 bn in 2014. The report is titled “Geriatric Medicines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” and it projects the market to expand at a CAGR of 7.3% between 2015 and 2023.
Geriatric medicines are concerned with administering specialist medical care for elderly people. These medicines mainly deal with the diagnosis, treatment, remedial, prevention, and social aspects relating to illnesses of older people, mainly patients who are 65 years or older. The rising incidence of diseases such as cancer, neurological disorders, cardiovascular disorders, and rheumatoid arthritis has been the prime driver of the global geriatric medicine market. The market is also gaining impetus from the increasing use of multiple medicines that may cause adverse side effects.

Read Report Overview: http://www.transparencymarketresearch.com/geriatric-medicine-market.html

The global geriatric medicine market has been exhibiting growth at an impressive rate. Apart from the increasing geriatric population, rising prevalence of chronic ailments, and the increasing investments in the national healthcare systems, particularly in developing nations, will boost the global geriatric medicines market. Despite witnessing positive growth worldwide, the lack of hospitals and specialized care centers is likely to hamper the market’s growth to an extent.
The report compiles exhaustive information relating to the factors influencing the market’s trajectory. For the purpose of the study, the market has been classified based on various parameters. By therapeutic category, the report has segmented the global geriatric medicines market into antihypertensive, antidiabetic, statins, proton pump inhibitor, antipsychotic, anticoagulant, and others. Of these, the analgesic segment held the largest share in the market in 2014. The segment is also projected to continue dominating the market through the forecast period.
As per the findings covered in the report, approximately 60% to 70% of people aged 65 years or above complain of some form of persistent pain or other. The most common pain complaints among older people include musculoskeletal pain, osteoarthritic pain, chronic joint pain, and peripheral pain. The demand from the analgesic segment is therefore spurred due to the increasing incidence of such chronic pains, coupled with favorable government initiatives promoting effective healthcare.

Request Sample of Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2445

In terms of conditions, the global geriatric medicines market has been segmented into arthritis, cardiovascular disorders, neurological ailments, respiratory disorders, osteoporosis, and others. Of these, the cardiovascular segment accounted for the largest share in the market in 2014. The report presents insights into various factors fuelling demand from the aforementioned segments.
Regionally, the report has classified the global geriatric medicines market into North America, Asia Pacific, Latin America, Europe, and the Middle East and Africa. Among these regions, North America accounted for the dominant share of 39% in the market in 2014, trailed by Europe. However, Asia Pacific, during the forecast period, is expected to exhibit the fastest CAGR. The rising prevalence of chronic ailments and increasing geriatric population in the region, coupled with increasing expenditure on healthcare infrastructure in most developing nations will aid the expansion of the geriatric medicines market in Asia Pacific.

Buy Geriatric Medicines Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=2445&ltype=S

To present an in-depth study on the vendor landscape, the report also profiles companies such as Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Merck & Company Inc., Pfizer, Inc., Novartis AG, and others.